



Clinical Trial Details (PDF Generation Date :- Fri, 16 Apr 2021 20:13:47 GMT)

CTRI Number	CTRI/2020/08/027477 [Registered on: 31/08/2020] - Trial Registered Prospectively	
Last Modified On	06/12/2020	
Post Graduate Thesis	No	
Type of Trial	Interventional	
Type of Study	Drug Ayurveda	
Study Design	Single Arm Trial	
Public Title of Study	Evaluation of safety and efficacy of T-AYU-HM Premium and Onion steam vaporization/nebulization in Covid-19 patients.	
Scientific Title of Study	Evaluation of safety and efficacy of T-AYU-HM Premium and Onion Steam vaporisation/nebulization in Covid-19 patients (mild to moderate)	
Secondary IDs if Any	Secondary ID	Identifier
	NIL	NIL
Details of Principal Investigator or overall Trial Coordinator (multi-center study)	Details of Principal Investigator	
	Name	Dr Atul M Desai
	Designation	Proprietor
	Affiliation	Dhanvantari Clinic, Ayurveda health care and research center
	Address	Room no: 301, Ayurveda, Shreeji Desai market, Sardar Chowk Vyara-394650, Gujarat. India Surat GUJARAT 394650 India
	Phone	9879031621
	Fax	
	Email	dratuldesai@rediffmail.com
Details Contact Person (Scientific Query)	Details Contact Person (Scientific Query)	
	Name	Dr Atul M Desai
	Designation	Proprietor
	Affiliation	Dhanvantari Clinic, Ayurveda health care and research center
	Address	Room no: 301, Ayurveda, Shreeji Desai market, Sardar Chowk Vyara-394650, Gujarat. India Surat GUJARAT 394650 India
	Phone	9879031621
	Fax	
	Email	dratuldesai@rediffmail.com
Details Contact Person (Public Query)	Details Contact Person (Public Query)	
	Name	Dr Hemshree Desai
	Designation	MD
	Affiliation	ATBU Harita Pharmaceuticals PVT LTD
	Address	ATBU Harita Pharmaceuticals Pvt Ltd. Room No:110, Shreeji Desai Market Sardar Chowk Vyara Surat GUJARAT 394650 India



Phone	9558054500			
Fax				
Email	hemshree94@gmail.com			
Source of Monetary or Material Support	Source of Monetary or Material Support			
	> ATBU Harita Pharmaceuticals Pvt Ltd. 110, Shreeji Desai Market, Sardar Chowk Vyara - 394650, Gujarat, India > Dhanvantari Clinic, Ayurveda Health Care and Research Center 301, Shreeji Desai market, Sardar Chowk Vyara-394650, Gujarat. India			
Primary Sponsor	Primary Sponsor Details			
	Name	Dhanvantari Clinic Ayurveda Health Care and Research Center		
	Address	Shreeji Desai Market, Vyara-394650, Gujarat. India		
	Type of Sponsor	Private hospital/clinic		
Details of Secondary Sponsor	Name	Address		
	ATBU Harita Pharmaceuticals Pvt Ltd	Vyara,Gujarat,India. Email: atbuharita@gmail.com		
Countries of Recruitment	List of Countries			
	India			
Sites of Study	Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
	Dr Atul Desai	Dhanvantari Clinic, Ayurveda Health Care and Research Center	Shreeji Desai Market, Vyara-394650, Gujarat. India Surat GUJARAT	9879031621 dratuldesai@rediffmail.com
	Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
	DivyajyotiTrust	Approved	19/08/2020	No
Regulatory Clearance Status from DCGI	Status	Date		
	Not Applicable	No Date Specified		
Health Condition / Problems Studied	Health Type	Condition		
	Patients	Coronavirus as the cause of diseases classified elsewhere		
Intervention / Comparator Agent	Type	Name	Details	
	Intervention	Tablet T-AYU-HM Premium	600mg orally BD for 21 days.	
	Intervention	Onion steam vaporization/nebulisation	Nasally OD for 21 days	
	Comparator Agent	NA	NA	
Inclusion Criteria	Inclusion Criteria			
	Age From	18.00 Year(s)		
	Age To	80.00 Year(s)		
	Gender	Both		
	Details	1. Age 18-80 years, 2. Both male and female 3. Mild to Moderate cases under home quarantine. 4. Willing to perform onion vaporization/nebulization? once a day 5. Patients able to consume oral formulations. 6. Willing to provide informed consent. 		
Exclusion Criteria	Exclusion Criteria			
	Details	1. Require mechanical ventilation 2. Unable to perform onion vaporization/nebulisation once a day.		



		3. Having serious stages illness 4. Pregnant/lactating women 5. Children below 18 years age				
Method of Generating Random Sequence	Not Applicable					
Method of Concealment	Not Applicable					
Blinding/Masking	Open Label					
Primary Outcome	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>1. Total number of participants with improvement in clinical symptoms – fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia). 2. Total number of participants with resolution of clinical symptoms fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia).</td> <td>21 days</td> </tr> </tbody> </table>		Outcome	Timepoints	1. Total number of participants with improvement in clinical symptoms – fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia). 2. Total number of participants with resolution of clinical symptoms fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia).	21 days
Outcome	Timepoints					
1. Total number of participants with improvement in clinical symptoms – fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia). 2. Total number of participants with resolution of clinical symptoms fever, Cough, Fatigue, Shortness of breath, Expectoration, Myalgia, Rhinorrhoea, Sore throat, Diarrhoea, Loss of smell (anosmia), Loss of taste (ageusia).	21 days					
Secondary Outcome	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>1. Oxygen requirement of patients 2. Improvement in oxygen saturation 3. Improvement in respiratory rate 4. Improvement in haematological parameters 5. Improvement in the level of other inflammatory markers CRP, ESR, LDH</td> <td>Baseline 5th day 21th day</td> </tr> </tbody> </table>		Outcome	Timepoints	1. Oxygen requirement of patients 2. Improvement in oxygen saturation 3. Improvement in respiratory rate 4. Improvement in haematological parameters 5. Improvement in the level of other inflammatory markers CRP, ESR, LDH	Baseline 5th day 21th day
Outcome	Timepoints					
1. Oxygen requirement of patients 2. Improvement in oxygen saturation 3. Improvement in respiratory rate 4. Improvement in haematological parameters 5. Improvement in the level of other inflammatory markers CRP, ESR, LDH	Baseline 5th day 21th day					
Target Sample Size	Total Sample Size=30 Sample Size from India=30 Final Enrollment numbers achieved (Total)=30 Final Enrollment numbers achieved (India)=30					
Phase of Trial	Phase 2					
Date of First Enrollment (India)	03/09/2020					
Date of First Enrollment (Global)	No Date Specified					
Estimated Duration of Trial	Years=0 Months=0 Days=21					
Recruitment Status of Trial (Global)	Not Applicable					
Recruitment Status of Trial (India)	Completed					
Publication Details	NIL					
Brief Summary	<p>This study is a single arm, open label trial to evaluate the safety and efficacy of T-AYU-HM Premium 600 mg BD for 21 days and Onion steam</p>					



vaporization/nebulization OD for 21 days in patients with COVID 19 that will be conducted at Dhanvantari Clinic, Ayurveda Health Care and Research Centre in India. The primary outcome measures will be improvement in clinical symptoms - cough, fever with or without chills, difficulty in breathing, headache, sore throat and resolution of clinical symptoms by the end of the treatment. Secondary outcomes will be reduction in oxygen requirement of patients, improvement in oxygen saturation, improvement in respiratory rate, improvement in hematological parameters, improvement in the level of inflammatory markers.